MLTX
MoonLake Immunotherapeutics
11.70$
+2.2%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | – | +2,662.5% | +124.5% | +274.3% | +88.9% | |
| – | – | -11.1% | -26.4% | +2.5% | +77.1% | |
| – | – | – | – | – | – | |
| – | – | -135.2% | – | – | – | |
| – | – | -68.4% | +1,674.0% | +82.9% | -93.3% | |
| – | -100.0% | +63,675.6% | -22.1% | +716.4% | – | |
| – | – | – | – | – | – | |
| – | – | – | -100.0% | – | – | |
| – | – | +25,734.0% | -100.0% | – | – | |
| – | -62.9% | +176.7% | +300.8% | -89.3% | +184.5% | |
| – | +401.7% | +369.4% | +1,208.2% | -165.8% | – | |
| – | – | – | – | – | – |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.